The FDA announced today that they have approved Victoza (liraglutide), a once-daily injection to treat type 2 diabetes in some adults.
Here are some snippets from the press release:
Victoza is in a class of medicines known as glucagon-like peptide-1 (GLP-1) receptor agonists that help the pancreas make more insulin after eating a meal.
Victoza is intended to help lower blood sugar levels along with diet, exercise, and selected other diabetes medicines. It is not recommended as initial therapy in patients who have not achieved adequate diabetes control on diet and exercise alone.